SecBot SecBot

CGON

CG Oncology, Inc.
Nasdaq· Biological Products, (No Diagnostic Substances)· Inc. DE· CIK 0001991792 Biotech & Drug Discovery
$84.78 +10.38 (+13.95%)
Nov 16 4:00 PM ET · prev $74.40
Market cap
$6.6B
Mid cap
Consensus
Buy
90% Buy or better · 21 analysts
Median target
🔒 Subscribers only
1 year
+105.5%
from $41.25 · Nov 17
30 days
+41.4%
from $59.96
52-week range
$37.37–84.78
at the high
Avg volume 20D
1.64M
Nov 16 spike 9.88M
Short interest
9.22M
≈10.3% of shares · +3.9%
Days to cover
11.0
at average volume
Insider net
+$20.6M
1 buyer · 2 sellers · 12 mo
New fund stakes
2
Q3 2026 13F · 2 exits
Filing reports
20
analyzed by SecBot
SecBot read BULLISH 8 reports · 90 days
Balance 1 bearish · 2 bullish · 1 mixed · 4 neutral oldest → newest, height = score
Avg score ·High conf. 4/8

Price

Daily candles with volume. Callouts mark insider and congressional trades, rating changes, 13F stakes, reports, catalysts, court and regulator actions, Reddit spikes and short-interest jumps. Hover one for the details (tap on phones).

Signal stack

Where each data set points today.

  • InsidersBULLISH

    1 insider bought $24.8M at an average $66.87. 2 insiders sold $4.2M. Price is 27% above their cost.

  • InstitutionsBULLISH

    Q3 2026: 27 added (2 new), 14 trimmed or exited. Largest new: Public Sector Pension Investment Board $11.4M.

  • AnalystsBULLISH

    19 of 21 rate it Buy or better.

  • Short sellersSTEADY

    Short interest +3.9% to 9.22M shares. 11.0 days to cover, ≈10.3% of shares.

  • TrendUPTREND

    24% above its 50-day average. New closing high $84.78 on Nov 16.

Who's buying

13F· Q3 2026
2
new positions
2
exits
$11.4M
in new stakes · top 1 shown
FundMoveSharesValue
MORGAN STANLEYADD1,499,311$106.3M
BNP PARIBAS FINANCIAL MARKETSADD523,162$37.1M
Russell Investments Group, Ltd.ADD248,725$17.6M
MASSACHUSETTS FINANCIAL SERVICES CO /MA/ADD220,689$15.6M
PUBLIC SECTOR PENSION INVESTMENT BOARDNEW182,000$11.4M
DEUTSCHE BANK AG\TRIM142,344$10.1M
Invesco Ltd.DOUBLED142,210$10.1M
ALPS ADVISORS INCADD117,456$8.3M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

21 analysts
Buy 90% rate it Buy or better
Strong Buy5Buy14Hold2Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Nov 9, 2026Guggenheim
MAINTAIN
MAINTAINBuy
Nov 6, 2026Wedbush
MAINTAIN
MAINTAINOutperform
Aug 7, 2026RBC Capital
MAINTAIN
MAINTAINOutperform
Aug 7, 2026Piper Sandler
MAINTAIN
MAINTAINOverweight
Aug 7, 2026Truist Securities
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$24.8M
bought · 1 insider
$4.2M
sold · 2 insiders
+26.8%
vs their $66.87 cost
DateInsiderTypeValue
Oct 15, 2026
Kalofonos Isabel
Chief Commercial Officer
Oct 15, 2026
AWARD92,000 sh
Oct 15, 2026
POST LEONARD E
Director
Oct 15, 2026
SELL$30.8K
Oct 15, 2026
POST LEONARD E
Director
Oct 15, 2026
SELL$31.2K
Oct 15, 2026
POST LEONARD E
Director
Oct 15, 2026
EXERCISE$600.00
Sep 15, 2026
POST LEONARD E
Director
Sep 15, 2026
SELL$73.0K
Sep 15, 2026
POST LEONARD E
Director
Sep 15, 2026
EXERCISE$600.00
Aug 14, 2026
POST LEONARD E
Director
Aug 14, 2026
SELL$74.5K
Aug 14, 2026
POST LEONARD E
Director
Aug 14, 2026
EXERCISE$600.00

Earnings setup

Estimates

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only

Short side

FINRA· Oct 30, 2026
9,215,844
shares short
+3.9%
vs prior settlement
11.0
days to cover
≈10.3%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow, newest first.
Nov 16, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 Press
🔒 Fresh report (last 24h), subscribers only
Nov 16, 2026 FDA
🔒 Fresh data, subscribers only
Nov 6, 2026 SEC
CG Oncology reported Q3 2026 net loss of $56.9M ($0.64 per share), wider than the $43.8M loss a year ago, and total…
8-K · Impact 5/10
Nov 6, 2026 Press
CG Oncology reported Q3 2026 financial results showing a net loss of $56.9 million ($0.64 per share), widening from a…
Impact 4/10
Nov 3, 2026 SEC
Four institutional asset managers increased their CG Oncology positions in Q3 2026, with aggregate buying of $4.4M…
INST-CLUSTER · Impact 3/10
Oct 15, 2026 Insider
Kalofonos Isabel was granted 92,000 shares
Chief Commercial Officer
Oct 15, 2026 Insider
POST LEONARD E sold 500 shares
Director @ $61.65 ($30.8K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
1 drug tracked · Drug pipeline →
Recent
Nov 16, 2026
FDA
🔒 Fresh data, subscribers only
Nov 6, 2026
Announcement
CG Oncology Reports Third Quarter 2026 Financial Results and Provides Business Updates
DALLAS, Nov. 06, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today reported financial results for the third quarter ended September…
Nov 6, 2026
Earnings result
CGON Q3 2026 Earnings: EPS $-0.64 (+25.4% vs est)
Sep 2, 2026
Press release
CG Oncology to Present at Upcoming Investor Conferences in September
DALLAS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON) today announced that Arthur Kuan, Chairman, President & Chief Executive…
Aug 19, 2026
Press release
Kuehn Law Encourages Investors of CG Oncology, Inc. to Contact Law Firm
NEW YORK, Aug. 19, 2026 /PRNewswire/ -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors…

SecBot reports

20 filings · 5 press releases · 4 bullish · 3 bearish · 2 mixed · 11 neutral
All CGON filing & press-release reports (25)